A basic study of Cancer vaccine therapy using genetically modified iPSDCs targeting for a Cancer Stem Cell
| Project/Area Number |
15H06553
|
|---|
| Research Category |
Grant-in-Aid for Research Activity Start-up
|
| Allocation Type | Single-year Grants |
|---|
| Research Field |
Digestive surgery
|
|---|
| Research Institution | Wakayama Medical University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2015-08-28 – 2017-03-31
|
| Project Status |
Completed (Fiscal Year 2016)
|
| Budget Amount *help |
¥2,730,000 (Direct Cost: ¥2,100,000、Indirect Cost: ¥630,000)
Fiscal Year 2016: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2015: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
|
|---|
| Keywords | 腫瘍免疫 / iPSDCs / 癌ワクチン / 再生医療 / 癌幹細胞 / iPS細胞 / 腫瘍抗原遺伝子 / 樹状細胞 / 免疫治療 |
|---|
| Outline of Final Research Achievements |
We induced Yamanaka four factors into healthy human peripheral blood mononuclear cells (PBMCs) with Sendai virus vector, and iPS cells were established. In this case, it was carried out according to iPS cells derived from fibroblasts which we have carried out in our department. We induced differentiation into iPSDCs by various methods. As a result, it became clear that it is most efficient to induce differentiation with cytokine cocktail. It was found that iPSDCs obtained thereby had sufficient function as antigen presenting cells.
Next, the CEA gene was introduced into this iPSDCs and its antitumor effect was evaluated with a virtual antigen and a human cancer cell line with a Cr release assay to confirm tumor antigen specific antitumor effect.
|
Report
(3 results)
Research Products
(7 results)
